|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
KR100829674B1
(ko)
|
2000-05-19 |
2008-05-16 |
코릭사 코포레이션 |
단당류 또는 이당류계 화합물을 이용한 전염성 및 다른질병의 예방 및 치료 방법
|
|
AU8100101A
(en)
|
2000-08-04 |
2002-02-18 |
Corixa Corp |
New immunoeffector compounds
|
|
JP4212278B2
(ja)
|
2001-03-01 |
2009-01-21 |
日本たばこ産業株式会社 |
移植片拒絶反応抑制剤
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US6525028B1
(en)
|
2002-02-04 |
2003-02-25 |
Corixa Corporation |
Immunoeffector compounds
|
|
US6911434B2
(en)
|
2002-02-04 |
2005-06-28 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
|
|
IL164376A0
(en)
|
2002-04-03 |
2005-12-18 |
Applied Research Systems |
Ox4or binding agents, their preparation and pharmaceutical compositions containing them
|
|
US7550140B2
(en)
|
2002-06-13 |
2009-06-23 |
Crucell Holland B.V. |
Antibody to the human OX40 receptor
|
|
EP1537878B1
(en)
|
2002-07-03 |
2010-09-22 |
Ono Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
AU2004284090A1
(en)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
LDL receptor class A and EGF domain monomers and multimers
|
|
EP2418278A3
(en)
|
2005-05-09 |
2012-07-04 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
EP2097535B1
(en)
|
2006-12-07 |
2016-09-21 |
The Board of Trustees of the Leland Stanford Junior University |
Identification and isolation of acute myeloid leukemia stem cells
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
EP2535354B1
(en)
|
2007-06-18 |
2017-01-11 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
|
SG186656A1
(en)
|
2007-12-14 |
2013-01-30 |
Bristol Myers Squibb Co |
Binding molecules to the human ox40 receptor
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
EP3605088A1
(en)
|
2008-04-09 |
2020-02-05 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
|
HUE030807T2
(en)
|
2008-09-26 |
2017-05-29 |
Dana Farber Cancer Inst Inc |
Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
|
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
|
TWI729512B
(zh)
|
2008-12-09 |
2021-06-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
CN104961829B
(zh)
|
2009-11-24 |
2018-08-21 |
米迪缪尼有限公司 |
针对b7-h1的靶向结合剂
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US20110280877A1
(en)
|
2010-05-11 |
2011-11-17 |
Koji Tamada |
Inhibition of B7-H1/CD80 interaction and uses thereof
|
|
EA031849B1
(ru)
|
2010-08-23 |
2019-03-29 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ox40 и способы их применения
|
|
AU2012233652B2
(en)
|
2011-03-31 |
2017-05-18 |
Centre Leon Berard |
Antibodies directed against ICOS and uses thereof
|
|
BR122022000334B1
(pt)
|
2011-08-01 |
2023-03-21 |
Genentech, Inc |
Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
KR102702287B1
(ko)
|
2012-05-15 |
2024-09-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
|
|
WO2014055897A2
(en)
|
2012-10-04 |
2014-04-10 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
AR093788A1
(es)
|
2012-12-04 |
2015-06-24 |
Oncomed Pharm Inc |
Inmunoterapia con agentes de enlace
|
|
RU2702108C2
(ru)
|
2013-07-16 |
2019-10-04 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
|
|
JP2016530267A
(ja)
*
|
2013-08-22 |
2016-09-29 |
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ |
癌及びウイルス感染症を治療するための免疫受容体調節
|
|
HUE063307T2
(hu)
*
|
2013-08-22 |
2024-01-28 |
The Council Of The Queensland |
Rák és vírusfertõzések kezelésére szolgáló immunreceptor-moduláció
|
|
US20160355589A1
(en)
*
|
2014-08-19 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Anti-tigit antibodies
|
|
CN107708741A
(zh)
*
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
EP3565889B1
(en)
*
|
2017-01-06 |
2025-03-26 |
ImmunityBio, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
|
JP2020530859A
(ja)
*
|
2017-08-11 |
2020-10-29 |
ブリンク バイオメディカル エスエーエス |
免疫調節剤としてのｃｄ９６結合剤
|
|
WO2019091449A1
(zh)
|
2017-11-10 |
2019-05-16 |
江苏恒瑞医药股份有限公司 |
Cd96抗体、其抗原结合片段及医药用途
|
|
TWI816729B
(zh)
*
|
2017-12-30 |
2023-10-01 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
WO2021042019A1
(en)
|
2019-08-30 |
2021-03-04 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
|
AU2020355614B2
(en)
*
|
2019-09-27 |
2024-12-05 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|